Polypharmacy and Reversible Drug Induced QT Prolongation in a Patient with Advanced Cancer: Case Report

References

• Al-Khatib SM, LaPointe NMA, Kramer JM, Califf RM. What clinicians should know about the QT interval.JAMA. 2003;289(16):2120–7. doi:10.1001/jama.289.16.2120.
   PubMed Web of Science ®Google Scholar
• Vandenberk B, Vandael E, Robyns T. Which QT correction formulae to use for QT monitoring? J Am Heart Assoc. 2016;5(6):1–10. doi:10.1161/JAHA.116.003264.
   PubMed Web of Science ®Google Scholar
• Khatib R, Sabir FRN, Omari C, Pepper C, Tayebjee MH. Managing drug-induced QT prolongation in clinical practice. Postgrad Med J. 2021;97(1149):452–8. doi:10.1136/postgradmedj-2020-138661.
   PubMed Web of Science ®Google Scholar
• Gavioli EM, Guardado N, Haniff F, Deiab N, Vider E. The risk of QTc prolongation with antiemetics in the palliative care setting: a narrative review. J Pain Palliat Care Pharmacother. 2021;35(2):125–35. doi:10.1080/15360288.2021.1900491.
   PubMed Web of Science ®Google Scholar
• Mason JW, Moon TE. Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management. Cancer Manag Res. 2013;5(1):179–85. doi:10.2147/CMAR.S34352.
   PubMedGoogle Scholar
• Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54(1):1–13. doi:10.1016/j.psym.2012.11.001.
   PubMed Web of Science ®Google Scholar
• Giraud EL, Ferrier KRM, Lankheet NAG, Desar IME, Steeghs N, Beukema RJ, van Erp NP, Smolders EJ. The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview. Lancet Oncol. 2022;23(9):e406–e415. doi:10.1016/S1470-2045(22)00221-2.
   PubMed Web of Science ®Google Scholar
• Kim P, Masha L, Olson A, Iliescu C, Karimzad K, Hassan S, Palaskas N, Durand J-B, Leung CH, Lopez-Mattei J, et al. QT prolongation in cancer patients. Front Cardiovasc Med. 2021;8:613625. doi:10.3389/fcvm.2021.613625.
   PubMed Web of Science ®Google Scholar
• Roden DM. Clinical practice. Long-QT syndrome. N Engl J Med. 2008;358(2):169–76. doi:10.1056/NEJMcp0706513.
   PubMed Web of Science ®Google Scholar
• Hardy JR, Bundock D, Cross J, Gibbons K, Pinkerton R, Kindl K, Good P, Philip J. Prevalence of QTc prolongation in patients with advanced cancer receiving palliative care—a cause for concern? J Pain Symptom Manage. 2020;59(4):856–63. doi:10.1016/j.jpainsymman.2019.12.356.
   PubMed Web of Science ®Google Scholar
• Grindrod KA, Nagge J. Simplifying QT prolongation for busy clinicians. Can Fam Physician. 2019;65(4):268–70.
   PubMed Web of Science ®Google Scholar
• Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W, American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology, the Council on Cardiovascular Nursing, and the American College of Cardiology Foundation. Prevention of torsade de pointes in hospital settings: A scientific statement from the American heart association and the American college of cardiology foundation. Circulation. 2010;121(8):1047–60. doi:10.1161/CIRCULATIONAHA.109.192704.
   PubMed Web of Science ®Google Scholar
• Cheng JJ, Azizoddin AM, Maranzano MJ, Sargsyan N, Shen J. J. Polypharmacy in Oncology. Clin Geriatr Med. 2022;38(4):705–14. doi:10.1016/j.cger.2022.05.010.
   PubMed Web of Science ®Google Scholar
• Turcotte A, Achi S, Mamlouk O, Mandayam S. Electrolytes disturbances in cancer patients. Curr Opin Nephrol Hypertens. 2022;31(5):425–34. doi:10.1097/MNH.0000000000000819.
   PubMed Web of Science ®Google Scholar
• Fujiki A, Sakabe M. Differences in the slope of the QT-RR relation based on 24-hour Holter ECG recordings between cardioembolic and atherosclerotic stroke. Intern Med. 2016;55(20):2927–32. doi:10.2169/internalmedicine.55.6702.
   PubMed Web of Science ®Google Scholar
• McLean SL, Blenkinsopp A, Bennett MI. Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts. J Pain Palliat Care Pharmacother. 2013;27(2):132–5. doi:10.3109/15360288.2013.782937.
   PubMedGoogle Scholar
• Ozeki Y, Fujii K, Kurimoto N, Yamada N, Okawa M, Aoki T, Takahashi J, Ishida N, Horie M, Kunugi H, et al. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(2):401–5. doi:10.1016/j.pnpbp.2010.01.008.
   PubMed Web of Science ®Google Scholar
• Jackson CW, Sheehan AH, Reddan JG. Evidence-based review of the black-box warning for droperidol. Am J Health Syst Pharm. 2007;64(11):1174–86. doi:10.2146/ajhp060505.
   PubMed Web of Science ®Google Scholar
• Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG. QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother. 2005;39(3):543–6. doi:10.1345/aph.1E513.
   PubMed Web of Science ®Google Scholar
• Leppert W. The role of methadone in cancer pain treatment - A review. Int J Clin Pract. 2009;63(7):1095–109. doi:10.1111/j.1742-1241.2008.01990.x.
   PubMed Web of Science ®Google Scholar
• Kreutzwiser D, Tawfic QA. Methadone for pain management: a pharmacotherapeutic review. CNS Drugs. 2020;34(8):827–39. doi:10.1007/s40263-020-00743-3.
   PubMed Web of Science ®Google Scholar
• Yamanaka E, Chino S, Takasusuki T, Hamaguchi S, Yamaguchi S. Effect of Methadone on cardiac repolarization in Japanese cancer patients: A longitudinal study. Cardiol Ther. 2020;9(1):119–26. doi:10.1007/s40119-019-00156-4.
   PubMed Web of Science ®Google Scholar
• Lovell AG, Protus BM, Saphire ML, Kale SS, Lehman A, Hartman A. Evaluation of QTc interval prolongation among patients with cancer using enteral methadone. Am J Hosp Palliat Care. 2019;36(3):177–84. doi:10.1177/1049909118811904.
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF. (R)-methadone versus racemic methadone : what is best for patient care? Addiction. 2011;106(4):687–8. doi:10.1111/j.1360-0443.2011.03374.x.
   PubMed Web of Science ®Google Scholar
• Ansermort N, Albayrak O, Schlapfer J. Substitution of (R,S)-methadone by (R)-methadone: impact on QTc interval. Arch Intern Med. 2010;170(6):529–36.
   PubMedGoogle Scholar
• McPherson ML, Walker KA, Davis MP, Bruera E, Reddy A, Paice J, Malotte K, Lockman DK, Wellman C, Salpeter S, et al. Safe and appropriate use of methadone in hospice and palliative care: expert consensus white paper. J Pain Symptom Manage. 2019;57(3):635–45.e4. doi:10.1016/j.jpainsymman.2018.12.001.
   PubMed Web of Science ®Google Scholar
• Bertschy G, Eap CB, Powell K, Baumann P. Fluoxetin addition to methadone in addicts: pharmacokinetics aspects. Ther Drug Monit. 1996;18(5):570–2. doi:10.1097/00007691-199610000-00008.
   PubMed Web of Science ®Google Scholar
• Deodhar M, Rihani SBA, Darakjian L, Turgeon J, Michaud V. Assessing the mechanisms of fluoxetine-mediated CYP2D6 inhibition. Pharmaceutics. 2021;13(2):148. doi:10.3390/pharmaceutics13020148.
   PubMed Web of Science ®Google Scholar
• Woosley RL, Heise CW, Gallo T, et al. www.CredibleMeds.org., QTdrugs List; 2023. [last accessed March 13, 2023].
   Google Scholar